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Classification and management of allergic rhinitis patients
in general practice during pollen season
Over the previous decades, the prevalence of allergic
disorders has risen to epidemic proportions. Allergic
rhinitis (AR) is the most common allergic disease,
affecting up to 25% of the population worldwide. As a
result of its high and increasing prevalence, its significant
impact on quality of life (QoL), its association with
multiple comorbidities and the considerable costs in
terms of use of healthcare resources, school or work
absenteeism and loss of productivity, the disease repre-
sents a major global health concern.
Nevertheless, the burden and consequences of AR are
still often underestimated by healthcare providers,
patients and their environment. Too often, the disease is
underdiagnosed and remains mis- or un(der)treated,
which leads to uncontrolled symptoms affecting work,
home and social life.
To facilitate and standardize the management of AR
and to improve patient care – and consequently, patient
satisfaction and compliance – several clinical guidelines
have been developed. In 1994 and 2000, European
guidelines for AR (1, 2) were published, recommending
a step-wise treatment approach. In 1999, as a result of a
WHO initiative, the Allergic Rhinitis and Its Impact on
Asthma (ARIA) Working Group was founded. The
ARIA guidelines, resulting from this collaboration, are
directed towards managing comorbid rhinitis and asthma
as manifestations of one !united airway disease", rather
than as two separate diseases of the nose and the lung.
They also propose a step-wise treatment strategy for AR,
but unlike the European guidelines, the ARIA guidelines
are evidence-based (3).
Whereas rhinitis was previously classified into !sea-
sonal" and !perennial" (and by extension occupational)
based on the type of exposure, the ARIA group reviewed
and changed this classification into !intermittent" or
!persistent" AR, on the basis of the duration of disease.
The gradation of the severity of AR is based on the
impact on QoL, rather than on (nasal) symptom scores.
For most patients suffering from AR, the general
practitioner (GP) is the (first) point of contact and AR is
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identified as one of the top ten reasons for visits to
primary care clinics (4). Consequently, the management
of AR and the dissemination and implementation of
guidelines for AR in general practice receives much
attention.
Despite the evidence that a guided strategy is superior
to a non-guided one (5), the availability of rigorously
developed guidelines does not ensure their use in clinical
practice (6). We conducted this survey to evaluate
whether the current knowledge regarding diagnostic
methods and treatment regimes for AR is applied in
daily primary care practice and to further characterize the
different classes of AR, as described by ARIA.
Materials and methods
Design of the study
In this cross-sectional pharmaco-epidemiological survey, Belgian
GPs were asked to recruit consecutive patients who presented at their
practice with symptoms of AR during the months February to July
2003, reflecting the tree and grass pollen season. The GPs were
instructed to include amaximumof 10 consecutive patients, to allowa
fair distribution over the different practices. For every patient, a
questionnaire was completed by the GP during the consultation. The
questionnaire was designed in order to allow a classification of the
patients according to ARIA and included the following items:
• Patient demographics: age and gender;
• Duration of AR symptoms (number of days per week and
number of consecutive weeks per year);
• Impact of AR on the patient’s QoL, assessed by the four ARIA
questions defining the severity of AR (3);
• Clinical expression of AR and severity of symptoms, measured
on a four-point scale, evaluating whether AR is manifested by
these symptoms: 1 ¼ never/rarely, 2 ¼ occasionally, 3 ¼ fre-
quently, or 4 ¼ always;
• Most bothersome symptom (rhinorrhoea, nasal congestion,
nasal itch, sneezing or conjunctivitis);
• Method of allergy diagnosis [with or without allergy testing:
radioallergosorbent test (RAST) and/or skin test];
• Triggering allergens (confirmed by positive allergy test);
• Treatment prescribed by GP: oral or intranasal antihistamines,
nasal decongestants, intranasal or oral glucocorticosteroids,
intraocular antihistamines or cromones;
• Referral to specialist.
Patient characteristics, inclusion and exclusion criteria
In order to have an optimal reflection of the AR patient population
in daily practice, the exclusion criteria were reduced to a minimum:
patients currently receiving treatment for AR and pregnant women.
To avoid data based on hetero-anamnesis, the patients had to be
at least 14 years old. A total of 804 patients, 50.9% males and
49.1% females, aged 36.4 ± 16.1 years old, were enrolled.
Recruitment of general practitioners
To allow maximal spread, 125 GPs were contacted and asked to
participate in a total of 29 different geographical areas covering
Belgium. Ninety-five of the 125 GPs contacted agreed to participate,
77.9% males and 22.1% females. Among them, 63.8% were in solo
practice, and 36.2% in group practice. The distribution of the
participating GPs was homogeneous throughout Belgium: 56.8%
worked in Flanders, 35.8% in Wallonia and 7.4% in Brussels;
27.4% of the GPs practised in an area with a population density of
<250 inhabitants/km2, 24.2% in an area with 251–500 inhabitants/
km2, 25.3% in an area with 501–1000 inhabitants/km2 and 23.1% in
an area with more than 1000 inhabitants/km2 (7). On average, 8.5
patients per investigator were included.
Statistical analyses
The descriptional part of the study uses conventional parameters:
mean ± SD for quantitative variables; qualitative variables are
represented in terms of percentages. Differences between subgroups
are analysed using Chi-square test for nominal or ordinal values,
and Kruskal–Wallis test and Mann–Whitney U-test for quantitative
values. The significance level was set with an a risk ¼ 0.05. All
analyses were completed using SPSS Inc. (version 11; Chicago, IL,
USA).
Results
Duration, severity and ARIA classification of AR
In 36.1% of the patients, symptoms of AR were present
for more than four consecutive weeks and during more
than 4 days a week. In 42.1%, symptoms of AR were
present for four or less consecutive weeks and in 21.8%
symptoms of AR were present for more than four
consecutive weeks, but only during £ 4 days a week. In
accordance with the ARIA classification, 36.1% of the
patients were classified with persistent AR and 63.9%
were classified with intermittent AR.
Abnormal sleep was reported by 37.1% of the patients,
impairment of daily activities, sports or leisure by 71.3%,
impairment of work or school by 53.2% and troublesome
symptoms by 77.6%. One or more of these four QoL
items was (were) disturbed in 89.3% of the patients, who
were consequently categorized with moderate/severe
rhinitis (Table 1).
In the group of persistent rhinitics, all four QoL items
were more frequently disturbed, when compared with the
group of intermittent rhinitics. These differences reached
significance for abnormal sleep and troublesome symp-
toms. Consequently, AR was significantly more often
graded as moderate/severe in patients with persistent
disease than in those with intermittent disease (Table 2).
Table 1. Classification of the patients (n ¼ 804) into the four classes, as defined by
ARIA
Persistent Intermittent Total
Mild 17 (2.1) 69 (8.6) 86 (10.7)
Moderate–severe 273 (34.0) 445 (55.3) 718 (89.3)
Total 290 (36.1) 514 (63.9) 804 (100)
Values in parentheses represent percentages.
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Clinical presentation of AR
Allergic rhinitis was accompanied by sneezing in 89.7%
of the patients, by nasal congestion in 86.6%, by
rhinorrhoea in 85.9%, by nasal itch in 81.0%,
by conjunctivitis in 70.0%, by headache in 48.0% and
by somnolence in 37.9% (Fig. 1).
Patients with moderate/severe rhinitis demonstrated
significantly higher symptom scores for rhinorrhoea,
nasal congestion, nasal itch, conjunctivitis, headache
and somnolence compared with those with mild rhinitis
(Table 3). Patients with persistent rhinitis had signifi-
cantly higher scores for nasal congestion and somnolence
and borderline significantly higher scores for conjuncti-
vitis compared with those with intermittent rhinitis
(Table 2).
Of all patients, 38.3% were predominantly bothered by
nasal congestion, 28.0% by rhinorrhoea, 17.3% by
conjunctivitis, 9.8% by sneezing and 6.6% by nasal itch.
Patients predominantly suffering from nasal congestion
reported significantly more abnormal sleep than all other
patients (42.5% vs 33.7%, P ¼ 0.01), whereas patients
especially bothered by conjunctivitis reported more
impairment of daily activities, sport and leisure compared
with all other patients (78.4% vs 69.6%, P ¼ 0.05) (data
not shown).
Table 2. Clinical presentation of patients with intermittent vs persistent allergic
rhinitis
Intermittent
(n ¼ 514)
Persistent
(n ¼ 290) P-value
Male/female 1.05 1.01 NS
Age in years (mean € SD) 36.1 € 15.9 36.8 € 16.5 NS
Impaired sleep (%) 33.5 43.4 0.006
Impaired daily activities/leisure/sports (%) 69.8 73.8 NS
Impaired school/work (%) 51.4 56.6 NS
Troublesome symptoms (%) 73.5 84.8 <0.001
Moderate/severe AR (%) 86.6 94.1 0.001
Symptom scores (% with score 3 or 4)
Rhinorrhoea 59.1 59.3 NS
Nasal congestion 58.4 66.2 0.03
Nasal itch 50.2 43.8 NS
Sneeze 61.9 62.4 NS
Conjunctivitis 37.4 43.8 0.09
Headache 11.7 15.5 NS
Somnolence 6.8 13.8 0.002
NS, no statistical significance.
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Figure 1. Symptomatology of allergic rhinitis and severity of the manifestations.
Table 3. Clinical presentation of patients with mild vs moderate/severe allergic
rhinitis
Mild
(n ¼ 86)
Moderate/severe
(n ¼ 718) P-value
Male/female 1.05 1.03 NS
Age in years (mean € SD) 38.8 € 18.5 36.1 € 15.8 NS
Symptom scores (% with score 3 or 4)
Rhinorrhoea 47.7 60.6 0.03
Nasal congestion 39.5 63.8 <0.001
Nasal itch 32.6 49.7 0.004
Sneeze 58.1 62.5 NS
Conjunctivitis 26.7 41.2 0.01
Headache 5.8 13.9 0.05
Somnolence 0.0 10.4 0.003
NS, no statistical significance.
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Allergy diagnosis and responsible allergens
Of all patients, 47% had never undergone allergy testing
to confirm the allergic basis of rhinitis. In 32%, RAST
and/or skin tests had been performed in the last 2 years,
and in 21% more than 2 years ago. The prevalence of
allergy testing was significantly higher in the group of
persistent rhinitics compared with intermittent rhinitics
(69.3% vs 44.2%, P < 0.001) and in the moderate/severe
group compared with the mild AR group (54.6% vs
41.9%, P ¼ 0.03) (data not shown).
In 351 of the 428 !tested" patients, the cause of allergy
was known: 65.2% of the patients were allergic to grass
pollen, 63.8% to tree pollen, 63.0% to house dust mite
(HDM) and 37.0% to animal dander. No significant
differences were found between intermittent and persist-
ent rhinitics in the prevalence of allergy caused by grass
pollen (65.4% and 65.1%, respectively), tree pollen
(62.7% and 53.6%, respectively), HDM (58.4% and
68.1%, respectively) or animal dander (34.6% and
39.8%, respectively).
Overall, 50.7% of the patients were allergic to both
seasonal (grass and/or tree pollen) and perennial allergens
(HDM and/or animal dander). In 82.5% of the persistent
rhinitics, symptoms were provoked by at least one
seasonal allergen (grass and/or tree pollen) and in
71.9% of those classified with intermittent rhinitics, AR
was triggered by at least one perennial allergen (HDM
and/or animals).
Prescribed treatment and specialist referral
None of the patients was on treatment for AR at the time
of the visit (was part of the exclusion criteria). At the
end of the visit, only one medication was prescribed in
29.6% of the patients, 67.2% received a combination
therapy and 3.2% received no prescription for medica-
tion. Overall, topical treatment was recommended in
14.2%, oral therapy in 21.3%, while 61.3% received a
combination of oral and topical medication. Oral anti-
histamines were the most frequently prescribed pharma-
cological agents (82.2%), followed by intranasal
glucocorticosteroids (58.2%), nasal decongestants
(18.6%), topical eye treatment (intraocular antihistamine
or cromone) (17.3%), nasal antihistamines (9.2%) and
oral glucocorticosteroids (5.3%).
Nine per cent of the patients were referred to a
specialist. Specialist referral was significantly more often
proposed in patients with persistent disease compared
with those with intermittent disease, but did not signifi-
cantly differ between patients with mild or moderate/
severe AR. Remarkably, 27.8% of the patients referred to
a specialist did not receive any initial treatment from their
GP.
Patients with mild AR more often received no medi-
cation than those with moderate/severe AR, but this
difference only reached borderline significance. Gluco-
corticosteroids were more often prescribed in persistent
rhinitics than in intermittent rhinitics and in the moder-
ate/severe group compared with the mild group. These
differences reached significance for intranasal glucocorti-
costeroids, but not for oral glucocorticosteroids (Tables 4
and 5). We also compared the proposed medication for
rhinitis symptoms in the different groups, defined by
ARIA, with the recommendations of the ARIA guide-
lines (Table 6).
Allergic rhinitis treatment in view of the main symptomatology
Among the patients who predominantly suffered from
nasal congestion, 70.1% were prescribed an intranasal
glucocorticosteroid, 20.8% a nasal decongestant and
4.2% an oral glucocorticosteroid, whereas 19.8% re-
ceived none of these potent anti-congestive agents.
Overall, patients who considered nasal congestion as the
most bothersome symptom more often received an
intranasal glucocorticosteroid (70.1% vs 50.6%,
P < 0.001) compared with other patients, but no
significant differences were found for nasal decongestants
or oral glucocorticosteroids (data not shown).
Patients mostly bothered by eye symptoms received
an intraocular cromone or intraocular antihistamine in
44.6% of the cases compared with 11.6% in the
other patients (P < 0.001); 48.5% did not receive
Table 4. Therapeutic management of patients with intermittent vs persistent
allergic rhinitis
Intermittent
(n ¼ 514)
Persistent
(n ¼ 290) P-value
Oral antihistamines (%) 82.1 82.4 NS
Nasal antihistamines (%) 8.8 10 NS
Nasal glucocorticosteroids (%) 53.1 67.2 <0.001
Oral glucocorticosteroids (%) 4.9 6.2 NS
Nasal decongestants (%) 18.3 19.3 NS
Topical eye medication (%) 14.6 22.1 0.009
No medication prescribed (%) 3.3 3.1 NS
Specialist referral (%) 7.0 12.4 0.01
NS, no statistical significance.
Table 5. Therapeutic management of patients with mild vs moderate/severe
allergic rhinitis
Mild
(n ¼ 86)
Moderate/severe
(n ¼ 718) P-value
Oral antihistamines (%) 62.8 84.5 <0.001
Nasal antihistamines (%) 8.1 9.3 NS
Nasal glucocorticosteroids (%) 40.7 60.3 <0.001
Oral glucocorticosteroids (%) 1.2 5.8 NS
Nasal decongestants (%) 22.1 18.2 NS
Topical eye medication (%) 12.8 17.8 NS
No medication prescribed (%) 7.0 2.8 0.08
Specialist referral (%) 7.0 9.2 NS
NS, no statistical significance.
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topical eye medication, but were prescribed an oral
antihistamine for the treatment of their allergic
rhinoconjunctivitis.
Discussion
For patients suffering from AR, the GP is often the first
point of contact. As many rhinitis patients rely on their
GP for the diagnosis and treatment of their symptoms,
general healthcare practices represent an interesting and
important target to evaluate the management of AR. The
ARIA guidelines currently provide diagnostic and thera-
peutic recommendations for AR with the best evidence.
Our study was conducted 2 years after publication of the
ARIA document, primarily to assess whether the criteria
for diagnosis and the standards for effective treatment are
applied in everyday primary care practice (in Belgium).
Whereas ARIA insists on performing highly sensitive
and specific in vivo or in vitro allergy tests to confirm or
exclude an allergic aetiology of rhinitis, we found that
only half of the patients diagnosed with AR by their GP,
had ever undergone allergy testing. In addition, less than
10% were referred to a specialist for further diagnostic or
therapeutic management. These figures are similar to
previous results (7, 8), and indicate that GPs do not
commonly confirm or support their diagnosis of AR by
skin or in vitro allergy tests and rarely ask advice from a
specialist. In most cases, the diagnosis of AR is based on
a typical clinical picture, consisting of sneezing, nasal
congestion, rhinorrhoea, nasal itch and often also con-
junctivitis. In our study, these manifestations were part of
the symptomatology in 90%, 87%, 86%, 81% and 70%
of the patients, respectively. Although allergy tests were
not routinely performed, we may assume that the number
of falsely diagnosed allergic rhinitics is rather small, as the
predictive value of clinical history alone in the diagnosis
of AR has been shown to vary between 82% and 85% for
seasonal allergens and to be at least 77% for perennial
allergens (9).
Similar to other pharmaco-epidemiological trials (7,
10), oral antihistamines were by far the most commonly
prescribed first-line medications (82%). Despite previous
reports that GPs seem to have some reluctance to use
nasal glucocorticosteroids for the treatment of AR (11),
we found a rather high prescription rate, especially in
patients with persistent (67%) or moderate/severe AR
(60%) and in patients predominantly bothered by nasal
congestion (70%). Currently, there is no proof for the
additional beneficial effects of the combination of an
intranasal corticosteroid and an antihistamine compared
with an intranasal corticosteroid alone (12), but many
experts feel that the former has a superior value (2). This
is also reflected in the pharmacological treatment,
presented by the GPs in our study, with the combination
of these two agents (with or without addition of a nasal
decongestant) prescribed in 15% of the mild intermittent,
35% of the mild persistent, 46% of the moderate/severe
intermittent and 54% of the moderate/severe persistent
rhinitis patients.
Nasal decongestants are very effective for the rapid
relief of nasal congestion, but as they do not improve
nasal itch, sneezing or rhinorrhoea and hold a significant
risk for rebound rhinitis in case of prolonged adminis-
tration, their use(fulness) is limited. The GPs in our study,
nevertheless, prescribed these agents in 20% of the
patients and, remarkably, a similar prescription rate
was found in patients who were and who were not
predominantly bothered by nasal congestion! Oral gluco-
corticosteroids, on the other hand, are never recommen-
ded as a first-line treatment option for AR, but are
preserved for the more treatment-resistant cases of AR.
Belgian GPs, however, prescribed them as first-line
treatment to 5% of the patients.
In patients with mild and/or intermittent disease,
rhinitis symptoms were treated according to the ARIA
guidelines in 47% of the cases, were undertreated in only
4%, and were overtreated in 49%. Overtreatment mainly
consisted of the prescription of nasal glucocorticosteroids
to the mild intermittent group and the combination of a
nasal glucocorticosteroid and an antihistamine in the
mild persistent and moderate/severe intermittent groups.
Table 6. Prescribed medication for rhinitis in the different patient groups, classified
according to ARIA
Mild
intermittent
(n ¼ 69)
Mild
persistent
(n ¼ 17)
Moderate/
severe
intermittent
(n ¼ 445)
Moderate/
severe
persistent
(n ¼ 273)
ND 3 (4.3) – 5 (1.1) 1 (0.4)
AH 21 (30.4) 4 (23.5) 134 (30.1) 60 (22.0)
AH + ND 15 (21.7) – 29 (6.5) 10 (3.7)
NGCS 11 (15.9) 7 (41.2) 30 (6.7) 16 (5.9)
NGCS + ND 1 (1.4) – 4 (0.9) 9 (3.3)
NGCS + AH 10 (14.5) 6 (35.3) 178 (40) 122 (44.7)
NGCS + AH + ND – – 27 (6.1) 25 (9.2)
OGCS – – – –
OGCS + AH 1 (1.4) – 7 (1.6) 5 (1.8)
OGCS + ND – – 2 (0.4) –
OGCS + AH + ND – – 4 (0.9) 3 (1.1)
OGCS + NGCS – – 1 (0.2) –
OGCS + NGCS + AH – – 6 (1.3) 2 (0.7)
OGCS + NGCS + ND – – – 1 (0.3)
OGCS + NGCS + AH + ND – – 5 (1.1) 7 (2.6)
No rhinitis medication 7 (10.1) – 13 (2.9) 12 (4.4)
Treated according
to ARIA (%)
56.5 64.7 45.4 63.0
!Undertreated" (%) 10.1 0.0 2.9 30.4
!Overtreated" (%) 33.3 35.3 51.7 6.6
Values in parentheses represent percentages.
ND, nasal decongestant; AH, oral or intranasal antihistamine; NGCS, nasal gluco-
corticosteroid; OGCS, oral glucocorticosteroid.
Treated according to ARIA are unshaded; undertreated compared with ARIA rec-
ommendations are light shaded; overtreated compared with ARIA recommendations
are dark shaded.
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It can, however, barely be judged as !incorrect" to choose
the most effective treatment option, when this therapy has
proven to be safe and when these agents are available,
affordable and acceptable for the patient. For moderate/
severe persistent rhinitis, on the other hand, nasal
glucocorticosteroids are the first-choice treatment, but,
almost one-third of this patient group was insufficiently
treated.
From comparing the treatment strategies proposed by
the GPs with the ARIA recommendations, we might
conclude that the guidelines are only followed to some
extent by the GPs. Of course, it should be recognized that
the prescribed treatment is a result of an agreement
between doctor and patient, and therefore some devia-
tions from the gold standard are to be expected. In
addition, the choice of treatment may also be affected by
the presence of comorbid disease or the use of concom-
itant medication. In patients with comorbid asthma and
rhinitis, GPs may prefer to prescribe a systemic treatment
that is effective for both manifestations of the united
airway disease and leads to increased compliance, instead
of a combination of topical treatments. In patients,
especially children, already treated with inhaled cortico-
steroids for asthma, on the other hand, they may want to
limit the total glucocorticosteroid dose by choosing other
treatment options than intranasal glucocorticosteroids
for AR.
The results of this survey also allow us to formulate
some reflections on the old AR classification, based on
the type of exposure, and on the newer ARIA classifi-
cation, based on the duration of symptoms and their
impact on QoL. The inclusion period of our study was
limited to the tree and grass pollen season and this trial
has an obvious recruitment bias. An overrepresentation
of tree pollen- and grass pollen-allergic patients is
expected, and this spring survey cannot be used as an
epidemiological study to assess the proportion of
patients suffering from seasonal or perennial AR.
Nevertheless, our results do confirm that the previous
classification of AR is not applicable to real-life
situations as more than half of the patients had a
!mixed" form of AR, being allergic to both seasonal and
perennial allergens. Recently, the ARIA classification
has been validated by Demoly et al. in a medical
practice-based study in France (13) and by Bauchau et
al. in a population-based cross-sectional study in six
European countries (14, 15). Both trials demonstrated
that perennial allergens can cause intermittent symptoms
and that seasonal allergens can cause persistent symp-
toms. We found 80% of the patients classified with
persistent rhinitis to be allergic to tree or grass pollen,
and more than 70% of the intermittent rhinitics to be
allergic to perennial allergens. These results, together
and consistent with the findings of Demoly et al. and
Bauchau et al., demonstrate that persistent and inter-
mittent AR are not equivalent to or interchangeable
with perennial and seasonal AR, respectively. Further-
more, persistent rhinitis has shown to be clearly different
from and more debilitating than intermittent rhinitis.
Bauchau et al. reported a greater degree of self-aware-
ness and previous diagnosis, more severe symptoms, a
higher rate of doctor-prescribed medication and a more
regular use of medication in patients with persistent
compared with intermittent rhinitis (15). We found that
persistent rhinitics had a reduced QoL, marked by an
increased rate of troublesome symptoms and impaired
sleep, and that they reported more frequent symptoms
of somnolence, conjunctivitis and nasal congestion
compared with intermittent rhinitics. In addition, per-
sistent rhinitis was associated with a higher degree of
allergy testing and specialist referral.
Furthermore, in our study, moderate/severe AR was
associated with higher symptom scores for nasal conges-
tion, rhinorrhoea, nasal itch, conjunctivitis, headache and
somnolence and a higher rate of doctor-prescribed
medication compared with mild AR. This demonstrates
that the two severity categories for AR defined by ARIA
based on the impact of AR on QoL, indeed represent a
different burden of disease, also reflected by other
outcome measures. Another important observation, how-
ever is that, similar to the data of Demoly et al. (7, 10), up
to 90% of the patients were categorized with moderate/
severe rhinitis. In addition, Bauchau and Durham repor-
ted that 45% of the AR patients in the general population
are undiagnosed by a physician and that these previously
undiagnosed patients have lower symptom severity (14).
It may therefore be suggested that patients consulting
their physician are those with moderate/severe rhinitis,
whereas those with mild rhinitis often do not seek advice
from professional healthcare providers.
Conclusion
This study demonstrates that the ARIA guidelines are
often, but not always followed in general practice. To
improve the management of a global health problem with
increasing prevalence, further efforts are required to
disseminate and implement these evidence-based recom-
mendations in primary care practice. In addition, our
results support the validity of the ARIA classification and
provide more information on the characteristics of AR
patients in the different ARIA classification groups. A
year-around assessment in the general population, how-
ever, is required to make an epidemiologically correct
estimation of the proportion of AR patients in the four
ARIA classes.
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